Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ).
Shanghai Bio-heart Biological Technology Co., Ltd. has scheduled a board meeting on March 28, 2025, to consider and approve the company’s annual results for the year ending December 31, 2024, and to discuss the potential recommendation of a final dividend. This meeting is significant as it will determine the company’s financial performance and potential shareholder returns, impacting its market positioning and stakeholder interests.
More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-heart Biological Technology Co., Ltd. is a company incorporated in the People’s Republic of China, operating in the biotechnology sector. It focuses on developing biological technology solutions, although specific products or market focus are not detailed in the announcement.
YTD Price Performance: 95.12%
Average Trading Volume: 316,196
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$1.07B
For a thorough assessment of 2185 stock, go to TipRanks’ Stock Analysis page.